Literature DB >> 17158225

MafB negatively regulates RANKL-mediated osteoclast differentiation.

Kabsun Kim1, Jung Ha Kim, Junwon Lee, Hye Mi Jin, Hyun Kook, Kyung Keun Kim, Soo Young Lee, Nacksung Kim.   

Abstract

Receptor activator of nuclear factor kappaB ligand (RANKL) induces osteoclast formation from hematopoietic cells via regulation of various transcription factors. Here, we show that MafB negatively regulates RANKL-induced osteoclast differentiation. Expression levels of MafB are significantly reduced by RANKL during osteoclastogenesis. Overexpression of MafB in bone marrow-derived monocyte/macrophage lineage cells (BMMs) inhibits the formation of TRAP(+) multinuclear osteoclasts, but phagocytic activity of BMMs is retained. Furthermore, overexpression of MafB in BMMs attenuates the gene induction of NFATc1 and osteoclast-associated receptor (OSCAR) during RANKL-mediated osteoclastogenesis. In addition, MafB proteins interfere with the DNA-binding ability of c-Fos, Mitf, and NFATc1, inhibiting their transactivation of NFATc1 and OSCAR. Furthermore, reduced expression of MafB by RNAi enhances osteoclastogenesis and increases expression of NFATc1 and OSCAR. Taken together, our results suggest that MafB can act as an important modulator of RANKL-mediated osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17158225     DOI: 10.1182/blood-2006-09-048249

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  101 in total

1.  Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis.

Authors:  Jeske J Smink; Per-Ulf Tunn; Achim Leutz
Journal:  J Mol Med (Berl)       Date:  2011-11-10       Impact factor: 4.599

2.  Multicentric carpotarsal osteolysis is caused by mutations clustering in the amino-terminal transcriptional activation domain of MAFB.

Authors:  Andreas Zankl; Emma L Duncan; Paul J Leo; Graeme R Clark; Evgeny A Glazov; Marie-Claude Addor; Troels Herlin; Chong Ae Kim; Bruno P Leheup; Jim McGill; Steven McTaggart; Stephan Mittas; Anna L Mitchell; Geert R Mortier; Stephen P Robertson; Marie Schroeder; Paulien Terhal; Matthew A Brown
Journal:  Am J Hum Genet       Date:  2012-03-01       Impact factor: 11.025

3.  The transmembrane adaptor protein, linker for activation of T cells (LAT), regulates RANKL-induced osteoclast differentiation.

Authors:  Kabsun Kim; Jung Ha Kim; Jang Bae Moon; Jongwon Lee; Han Bok Kwak; Yong-Wook Park; Nacksung Kim
Journal:  Mol Cells       Date:  2012-02-28       Impact factor: 5.034

Review 4.  Osteoclastogenesis and arthritis.

Authors:  Nicola Maruotti; Maria Grano; Silvia Colucci; Francesca d'Onofrio; Francesco Paolo Cantatore
Journal:  Clin Exp Med       Date:  2010-11-11       Impact factor: 3.984

5.  Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development.

Authors:  Kaori Tsuji-Takechi; Takako Negishi-Koga; Eriko Sumiya; Akiko Kukita; Shigeaki Kato; Takahiro Maeda; Pier Paolo Pandolfi; Keiji Moriyama; Hiroshi Takayanagi
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

6.  MiR-30a attenuates osteoclastogenesis via targeting DC-STAMP-c-Fos-NFATc1 signaling.

Authors:  Yiran Yin; Lian Tang; Jieying Chen; Xiaobo Lu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

Review 7.  Does TNF Promote or Restrain Osteoclastogenesis and Inflammatory Bone Resorption?

Authors:  Baohong Zhao
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

8.  Identification of LRRc17 as a negative regulator of receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast differentiation.

Authors:  Taesoo Kim; Kabsun Kim; Seoung Hoon Lee; Hong-Seob So; Junwon Lee; Nacksung Kim; Yongwon Choi
Journal:  J Biol Chem       Date:  2009-03-31       Impact factor: 5.157

Review 9.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

10.  Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha.

Authors:  Kazunori Hamamura; Nancy Tanjung; Hiroki Yokota
Journal:  J Bone Miner Metab       Date:  2013-03-28       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.